New findings presented at MSVirtual2020 included long-term data from studies of the use of alemtuzumab and dimethyl fumarate.
In a session on disease-modifying therapies (DMTs) and risk management, Professor Alasdair Coles from the University of Cambridge School of Medicine, UK, presented data on the anti-CD52 monoclonal antibody therapy alemtuzumab in relapsing-remitting MS (RRMS)